NOA-05 phase II trial of procarbazine and CCNU therapy in gliomatosis cerebri
Annals of Neurology , 05/13/2011
Glas M et al. – Procarbazine and CCNU(PC) chemotherapy is effective in gliomatosis cerebri(GC). With the NOA–05 trial being the first prospective multicenter trial in GC, PC chemotherapy can be regarded as a promising option for the primary therapy of these tumors.
35 patients with previously untreated GC were treated with up to six 56–day courses of 110 mg/m2 CCNU on day 1 and 60 mg/m2 procarbazine on days 8 to 21.
Primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.
Failure–free survival rate at 8 months was 50.3%.
Median progression–free survival was 14 months.
At progression, 12 patients received salvage radiotherapy.
Median overall survival was 30 months. Multivariate analysis revealed isocitrate dehydrogenase 1 (IDH1) gene mutation (hazard ratio (HR) 0.11, 95%CI 0.02–0.58) and initial presentation without a bilateral symmetrical infiltration pattern on MRI (HR 0.07, 95%CI 0.01–0.54) as independent prognostic factors associated with prolonged survival.
DH1 mutation was significantly associated with MGMT promoter methylation and an oligodendroglial tumor component.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.